Population Pharmacokinetic Model of THC Integrates Oral, Intravenous, and Pulmonary Dosing and Characterizes Short- and Long-term Pharmacokinetics

Novel Δ9-tetrahydrocannabinol formulation Namisol® has beneficial pharmacokinetics and promising pharmacodynamic effects

(2012) Linda E. Klumpers et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits Δ9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans

(2012) Linda E. Klumpers et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Does olanzapine inhibit the psychomimetic effects of Δ9-tetrahydrocannabinol?

(2012) Daniël Kleinloog et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Manipulating brain connectivity with δ9-tetrahydrocannabinol: A pharmacological resting state FMRI study

(2012) Linda E. Klumpers et al.   NEUROIMAGE

Does intravenous Δ9-tetrahydrocannabinol increase dopamine release? A SPET study

(2010) Emma Barkus et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Disruption of Frontal Theta Coherence by Δ9-Tetrahydrocannabinol is Associated with Positive Psychotic Symptoms

(2010) Paul D Morrison et al.   NEUROPSYCHOPHARMACOLOGY

Disposition of smoked cannabis with high Δ9-tetrahydrocannabinol content: A kinetic model

(2010) Claudine C. Hunault et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Opposite Effects of Δ-9-Tetrahydrocannabinol and Cannabidiol on Human Brain Function and Psychopathology

(2009) Sagnik Bhattacharyya et al.   NEUROPSYCHOPHARMACOLOGY

The acute effects of synthetic intravenous Δ9-tetrahydrocannabinol on psychosis, mood and cognitive functioning

(2009) P. D. Morrison et al.   PSYCHOLOGICAL MEDICINE

Modelling of the concentration—effect relationship of THC on central nervous system parameters and heart rate — insight into its mechanisms of action and a tool for clinical research and development of cannabinoids

(2008) A. Strougo et al.   JOURNAL OF PSYCHOPHARMACOLOGY